Trials / Completed
CompletedNCT04368403
A Study of KHK4827 in Patients With Systemic Sclerosis
A Phase 1, Open-label, Multiple-dose Study of KHK4827 in Subjects With Systemic Sclerosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Exploratory evaluation of pharmacokinetics and safety of KHK4827 in subjects with systemic sclerosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK4827 | 210 mg every 2 weeks (Q2W), subcutaneous (SC) injection |
Timeline
- Start date
- 2017-10-06
- Primary completion
- 2019-01-31
- Completion
- 2025-03-31
- First posted
- 2020-04-29
- Last updated
- 2025-07-11
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04368403. Inclusion in this directory is not an endorsement.